Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News

Gamida Cell Completes Enrollment for Phase I/II Study of Second Pipeline Product Nicord® For Hematological Malignancies 


September 19, 2012 - (Gamida Cell) - "Gamida Cell, a leader in adult stem cell expansion technologies and products, announced today that it has completed enrollment for a Phase I/II clinical trial of NiCord, the company’s second pipeline product."  Read Full Article


Posted on 8-Oct-12 by Gallerno, Jacob
Tags: Science and Industry News
Trackback Url  |  Link to this post | Bookmark this post with: